 | • レポートコード：MRC2304A245 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に169.2億ドルであった世界の生物製剤受託製造市場規模が2022年に196.4億ドルに到達し、2027年までにCAGR 16.32％で成長して419.2億ドルへと拡大すると予測しています。当調査資料では、生物製剤受託製造の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（バイオシミラー、インスリン、インターフェロン、モノクローナル抗体、組換えホルモン）分析、プラットフォーム別（哺乳類、微生物）分析、治療領域別（自己免疫疾患、心血管疾患、感染症、代謝疾患、神経疾患）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、AbbVie, Inc.、Abzena Plc.、AGC Biologics、Ajinomoto Co., Inc.、Avid Bioservices, Inc.、Binex Co., Ltd.、Boehringer Ingelheim GmbH、Cambrex Corporation、Catalent, Inc.、Emergent BioSolutions Inc.、Fujifilm Holding Corporation、JSR Life Sciences, LLCなどが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の生物製剤受託製造市場規模：製品別 - バイオシミラーの市場規模 - インスリンの市場規模 - インターフェロンの市場規模 - モノクローナル抗体の市場規模 - 組換えホルモンの市場規模 ・世界の生物製剤受託製造市場規模：プラットフォーム別 - 哺乳類の市場規模 - 微生物の市場規模 ・世界の生物製剤受託製造市場規模：治療領域別 - 自己免疫疾患における市場規模 - 心血管疾患における市場規模 - 感染症における市場規模 - 代謝疾患における市場規模 - 神経疾患における市場規模 ・世界の生物製剤受託製造市場規模：地域別 - 南北アメリカの生物製剤受託製造市場規模 アメリカの生物製剤受託製造市場規模 カナダの生物製剤受託製造市場規模 ブラジルの生物製剤受託製造市場規模 ... - アジア太平洋の生物製剤受託製造市場規模 日本の生物製剤受託製造市場規模 中国の生物製剤受託製造市場規模 インドの生物製剤受託製造市場規模 韓国の生物製剤受託製造市場規模 台湾の生物製剤受託製造市場規模 ... - ヨーロッパ/中東/アフリカの生物製剤受託製造市場規模 イギリスの生物製剤受託製造市場規模 ドイツの生物製剤受託製造市場規模 フランスの生物製剤受託製造市場規模 ロシアの生物製剤受託製造市場規模 ... - その他地域の生物製剤受託製造市場規模 ・競争状況 ・企業情報 |
The Global Biologics Contract Manufacturing Market size was estimated at USD 16.92 billion in 2021 and expected to reach USD 19.64 billion in 2022, and is projected to grow at a CAGR 16.32% to reach USD 41.92 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biologics Contract Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines.
Based on Platform, the market was studied across Mammalian and Microbial.
Based on Therapeutic Area, the market was studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biologics Contract Manufacturing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biologics Contract Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biologics Contract Manufacturing Market, including AbbVie, Inc., Abzena Plc., AGC Biologics, Ajinomoto Co., Inc., Avid Bioservices, Inc., Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions Inc., Fujifilm Holding Corporation, JSR Life Sciences, LLC, Lonza Group AG, ProBioGen AG, Recipharm AB, Rentschler Biotechnologie GmbH, Samsung Biologics Co., Ltd., Siegfried Holding AG, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., and WuXi Biologics Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biologics Contract Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biologics Contract Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biologics Contract Manufacturing Market?
4. What is the competitive strategic window for opportunities in the Global Biologics Contract Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the Global Biologics Contract Manufacturing Market?
6. What is the market share of the leading vendors in the Global Biologics Contract Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the Global Biologics Contract Manufacturing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for biosimilars and vaccine production
5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
5.1.1.3. Key advantages such as cost and time saving offered by contract services
5.1.2. Restraints
5.1.2.1. Changing trade policies between countries
5.1.3. Opportunities
5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
5.1.4. Challenges
5.1.4.1. Concerns over the breach of intellectual property and patents
5.2. Cumulative Impact of COVID-19
6. Biologics Contract Manufacturing Market, by Product
6.1. Introduction
6.2. Biosimilar
6.3. Insulin
6.4. Interferons
6.5. Monoclonal Antibodies
6.6. Recombinant Hormones
6.7. Vaccines
7. Biologics Contract Manufacturing Market, by Platform
7.1. Introduction
7.2. Mammalian
7.3. Microbial
8. Biologics Contract Manufacturing Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular Diseases
8.4. Infectious Diseases
8.5. Metabolic Diseases
8.6. Neurology
8.7. Oncology
8.8. Ophthalmology
8.9. Respiratory Disorders
9. Americas Biologics Contract Manufacturing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biologics Contract Manufacturing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Biologics Contract Manufacturing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abzena Plc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AGC Biologics
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Ajinomoto Co., Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Avid Bioservices, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Binex Co., Ltd.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Boehringer Ingelheim GmbH
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cambrex Corporation
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Catalent, Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Emergent BioSolutions Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Fujifilm Holding Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. JSR Life Sciences, LLC
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Lonza Group AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. ProBioGen AG
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Recipharm AB
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Rentschler Biotechnologie GmbH
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Samsung Biologics Co., Ltd.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Siegfried Holding AG
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Thermo Fisher Scientific, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Toyobo Co. Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. WuXi Biologics Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing